ARS PHARMACEUTICALS INC (SPRY)
US82835W1080 - Common Stock
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024.
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ARS Pharmaceuticals (NASDAQ:SPRY) just reported results for the first quarter o...
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC)...
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023.
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips ARS Pharmaceuticals (NASDAQ:SPRY) just reported results for the fourth quarter ...
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Preparing to submit response to the FDA’s CRL for neffy® (epinephrine nasal spray) in Type I allergic reactions in early Q2 2024, following successful...
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
U.S. equities market is rallying, but there are still interesting investments to make, especially for these strong-buy stocks under $10.
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
Significant unmet need with 80-90% of patients with current epinephrine Rx not using as directed, and only ~15% of diagnosed severe Type I allergy...
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
neffy demonstrated statistically significant and clinically meaningful improvement in pruritus, hives, body surface area and erythema in...
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
Repeat doses of neffy under nasal allergen challenge demonstrate a pharmacokinetic profile greater than or similar to injection, and a pharmacodynamic...
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
Six posters and oral presentations to be presented, including efficacy data for neffy from two distinct clinical studies in oral food challenge induced...
(NASDAQ:SPRY)
ARS Pharmaceuticals reports Q3 2023 financial results, with a GAAP EPS of -$0.16.
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
Company is on track with ongoing repeat-dose study under allergen-induced allergic rhinitis conditions requested by U.S. FDA with topline data expected in...
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting ...
NASDAQ:SPRY Investor Notice: Investigation over Potential Securities Laws Violations by ARS Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 10/11/2023 -- ARS Pharmaceuticals, Inc. is under investigation on over potential securities laws violations in connection with certain financial statements.
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)
SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology
neffy resulted in robust responses on pharmacodynamic (PD) surrogates of efficacy observed even at 1 minute after dosing, and which were comparable to, or...